E-ISSN: 1307-394X
Successful Treatment of Refractory Childhood Pemphigus with Rituximab
PDF
Cite
Share
Request
Case Report
VOLUME: 11 ISSUE: 3
P: 0-0
September 2017

Successful Treatment of Refractory Childhood Pemphigus with Rituximab

J Turk Acad Dermatol 2017;11(3):0-0
DOI: 10.6003/jtad.17113c3
Ankur Sarin
Jushya Bhatia
Kailash Bhatia
1. Sri Aurobindo Institute of Medical Sciences, Indore, Madhya Pradesh, India.
No information available.
No information available
PDF
Cite
Share
Request

ABSTRACT

Observation:

Rituximab is an anti-CD 20 monoclonal antibody used to treat Chronic Lymphocytic Leukemia and Rheumatoid Arthritis. In dermatology, rituximab has gained popularity for the treatment of refractory pemphigus vulgaris. However, there are only a few case reports regarding the treatment of refractory childhood pemphigus with rituximab. We are reporting this case as childhood pemphigus is rare, and the safety of rituximab in children is unknown due to the paucity of studies.

Keywords:
Rituximab, childhood pemphigus, refractory pemphigus vulgaris